CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Down 54.0% in February

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the target of a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 6,400 shares, a decrease of 54.0% from the January 31st total of 13,900 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average trading volume of 10,000 shares, the short-interest ratio is currently 0.6 days.

Institutional Investors Weigh In On CollPlant Biotechnologies

Several large investors have recently made changes to their positions in CLGN. Wells Fargo & Company MN boosted its position in CollPlant Biotechnologies by 110.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock worth $30,000 after purchasing an additional 4,405 shares during the period. Renaissance Technologies LLC purchased a new position in CollPlant Biotechnologies in the fourth quarter valued at about $38,000. Benjamin Edwards Inc. acquired a new position in shares of CollPlant Biotechnologies during the third quarter worth about $112,000. AMH Equity Ltd boosted its position in shares of CollPlant Biotechnologies by 17.4% in the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock worth $419,000 after buying an additional 17,295 shares during the period. Finally, Villere ST Denis J & Co. LLC grew its stake in shares of CollPlant Biotechnologies by 24.4% in the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock valued at $2,407,000 after buying an additional 95,000 shares in the last quarter. Institutional investors and hedge funds own 21.69% of the company’s stock.

CollPlant Biotechnologies Price Performance

CollPlant Biotechnologies stock opened at $3.50 on Friday. The company has a market cap of $40.09 million, a price-to-earnings ratio of -2.27 and a beta of 0.86. CollPlant Biotechnologies has a 12 month low of $3.20 and a 12 month high of $6.75. The stock’s 50-day moving average is $3.77 and its 200-day moving average is $4.21.

CollPlant Biotechnologies (NASDAQ:CLGN) last posted its quarterly earnings results on Wednesday, November 27th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative net margin of 2,680.00% and a negative return on equity of 77.05%. During the same quarter in the previous year, the business posted ($0.38) earnings per share. Research analysts anticipate that CollPlant Biotechnologies will post -1.44 EPS for the current year.

Analyst Upgrades and Downgrades

CLGN has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of CollPlant Biotechnologies in a report on Friday, November 29th. D. Boral Capital reiterated a “buy” rating and issued a $14.00 price target on shares of CollPlant Biotechnologies in a report on Wednesday, February 12th.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.